Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2006

View Archived Issues

Snapshots: Ceftobiprole results presented at ICAAC

Studies test in vitro antibacterial activity of retapamulin

Disease control noted with PTK-787/ZK-222584 in non-small cell lung cancer

Dose-finding study of weekly ZK-EPO in refractory solid tumors completed

Phase II data show efficacy of casopitant in chemotherapy-induced nausea/vomiting

Enrollment completed in morphine study with Hylenex

Epinastine begins phase II in patients with seasonal allergic rhinitis

Additional phase III results of telavancin in cSSSI

Entry blocker peptide demonstrates activity against influenza viruses

CoDa completes Series A financing

NitroMed focuses resources on development of BiDil XR

Ariad grants license to Bellicum for Argent cell-signaling regulation technology

Immtech advances preclinical pipeline of antimicrobial drug candidates

Analysis of independent study of CellCept in myasthenia gravis

Otsuka launching Physuline in Japan

BiovaxID accepted into E.U. Drug Register for Rare Diseases

New phase I trial of inhaled formulation of ALN-RSV01

Adherex regains all rights to ADH-1

Phase III data for Fentora for breakthrough pain in chronic low back pain patients

New agents for gastrointestinal disorders described in recent GSK patents

Recent patents disclose novel agents for obesity and disorders of lipoprotein metabolism

Recent Janssen patent claims complement C1s inhibitors for autoimmune disorders

Nexium approved for treatment of Zollinger-Ellison syndrome

New indication sought for Herceptin in Europe

NDA filed for Sanctura XR in overactive bladder

Elan reports on the antihyperalgesic effects of their novel B1 receptor antagonist, ELN-441958

Preclinical activity of the novel antipsychotic RGH-188

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...